注射用血清ゴナドトロフィン市場レポート：動向、予測、競合分析 (2031年まで)

世界の注射用血清ゴナドトロフィン（注射用血清性腺刺激ホルモン）市場の将来性は有望で、豚、牛、羊、馬の各市場に機会があります。注射用血清ゴナドトロフィンの世界市場は、2025年から2031年にかけてCAGR 5.7％で成長すると予想されます。この市場の主な促進要因は、世界の不妊症の蔓延と生殖補助医療技術に対する需要の高まりです。

• Lucintel社の予測によると、種類別では1000IU/本が予測期間中に高い成長を遂げる見込みです。
• 用途別では、豚が最も高い成長が見込まれます。
• 地域別では、アジア太平洋が予測期間中に最も高い成長が見込まれます。

注射用血清ゴナドトロフィン市場の戦略的成長機会

注射用血清ゴナドトロフィン市場は、さまざまな用途のさまざまな分野で戦略的成長の可能性が見られます。不妊治療の需要が高いことから、利害関係者はこれらの成長機会を活用して市場参入を増やし、患者の需要に効果的に応えることができます。

• 新興市場への進出：新興市場、特にアジアとアフリカは、血清ゴナドトロフィン注射の成長に有利な機会を提供します。不妊症に悩む多くの患者は、不妊治療サービスや教育へのアクセスが向上することで恩恵を受けるため、これらの地域は市場拡大にとって貴重な存在となります。
• 併用療法の開発：血清ゴナドトロフィンは、他の不妊治療薬と併用することで治療効果を高めることができます。これにより、医療提供者は複雑な症例に対して包括的な治療を提供できるようになり、不妊治療サービスの質が向上します。
• 患者中心サービスへの投資：患者教育や患者中心のソリューションに重点を置く組織は、今後も競争優位を保つでしょう。患者が治療を理解し管理するためのリソースを提供することで、信頼が生まれ、アドヒアランスが向上し、市場での存在感が強まります。
• 研究開発への注力：LHRHやhCGのような血清ゴナドトロフィン製剤を常に最新に保つことは、競争力を維持するために不可欠です。混雑した市場において、企業は既存製品の用途を追加開発し、現在の製品を強化することで優位に立つことができます。
• コネクティブケア技術の活用：治療管理のためのモバイル・アプリケーションなどの技術の統合は、患者のエンゲージメントを高めることができます。この動向は新たな市場機会を生み出し、企業は治療プロセスを通じて患者をサポートする包括的なソリューションを提供できるようになります。

こうした戦略的成長機会は、注射用血清ゴナドトロフィンの分野における技術革新、患者志向、市場の進化への対応力の必要性を強調しています。

注射用血清ゴナドトロフィン市場促進要因・課題

注射用血清ゴナドトロフィン市場は、様々な技術的、経済的、規制的要因の影響を大きく受けます。進化する市場環境の中で成功を目指す利害関係者にとって、これらの動向を理解することは極めて重要です。

注射用血清ゴナドトロフィン市場を牽引する要因は以下の通り：

• 不妊率の増加：不妊率の上昇：不妊率の上昇は、治療の選択肢を求める人々の増加に伴い、注射用血清ゴナドトロフィンの需要を生み出しています。このようなニーズは、注射用製品の提供を拡大する企業の後押しとなっています。
• 生殖技術の進歩：体外受精や顕微授精などの技術革新は、血清ゴナドトロフィンの需要を促進しています。これらの進歩は患者に幅広い治療の選択肢を提供し、市場の成長に寄与しています。
• 不妊治療の受け入れ拡大：不妊治療に対する社会的受容の高まりに伴い、より多くの人々が助けを求めるようになり、その結果、血清ゴナドトロフィン注射の処方率が上昇し、市場機会が拡大しています。
• リプロダクティブ・ヘルスに対する政府の支援：多くの政府は、不妊治療を含むリプロダクティブ・ヘルスへの取り組みへの予算配分を増やしています。このような支援は意識を高めるだけでなく、血清ゴナドトロフィン療法へのアクセスを改善し、市場成長を促進します。

注射用血清ゴナドトロフィン市場の課題は以下の通り：

• 規制遵守とコスト：規制要件への対応により、製造コストが上昇し、製品上市が遅れる可能性があり、市場成長の障害となり、新製品の導入が制限されます。
• 市場の飽和と価格圧力：血清ゴナドトロフィン市場に参入する企業が増え、競争が激化しています。この飽和状態は価格の引き下げにつながり、メーカーの収益性と持続可能性に影響を与える可能性があります。
• 治療効果に関する懸念：患者の中には血清ゴナドトロフィン注射の有効性を疑問視する者もおり、治療を受けることをためらわせる可能性があります。教育や調査を通じてこのような懸念に対処することは、患者の信頼と受容を築くのに役立ちます。

注射用血清ゴナドトロフィン市場の参入企業一覧

同市場の企業は、提供する製品の品質に基づいて競争しています。この市場の主要企業は、製造施設の拡大、研究開発投資、インフラ開拓、バリューチェーン全体の統合機会の活用に注力しています。これらの戦略を通じて、注射用血清ゴナドトロフィン市場は、需要の増加に対応し、競争力を確保し、革新的な製品と技術を開発し、生産コストを削減し、顧客基盤を拡大しています。本レポートに掲載されている血清ゴナドトロフィン企業のプロファイルは以下の通りです。

• MSD Animal Health
• Ceva Sante Animale
• Syntex
• Bioveta
• Ningbo Sansheng Biological Technology
• Ningbo Second Hormone Factory
• Chifeng Bo-En Pharmaceutical
• Guangzhou Vbio-Pharma
• JALLY
• Ningbo Creator Animal Pharmaceutical

目次

第1章 エグゼクティブサマリー

第2章 世界の注射用血清ゴナドトロフィン市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析 (2019年～2031年)

• マクロ経済動向 (2019～2024年) と予測 (2025～2031年)
• 世界の注射用血清ゴナドトロフィン市場の動向 (2019～2024年) と予測 (2025～2031年)
• 世界の注射用血清ゴナドトロフィン市場：種類別
  • 1000 IU/本
  • 5000 IU/本
  • その他
• 世界の注射用血清ゴナドトロフィン市場：用途別
  • 豚
  • 牛
  • 羊
  • 馬
  • その他

第4章 地域別の市場動向と予測分析 (2019年～2031年)

• 世界の注射用血清ゴナドトロフィン市場：地域別
• 北米の注射用血清ゴナドトロフィン市場
• 欧州の注射用血清ゴナドトロフィン市場
• アジア太平洋の注射用血清ゴナドトロフィン市場
• その他地域の注射用血清ゴナドトロフィン市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界の注射用血清ゴナドトロフィン市場の成長機会：種類別
  • 世界の注射用血清ゴナドトロフィン市場の成長機会：用途別
  • 世界の注射用血清ゴナドトロフィン市場の成長機会：地域別
• 世界の注射用血清ゴナドトロフィン市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の注射用血清ゴナドトロフィン市場の生産能力拡大
  • 世界の注射用血清ゴナドトロフィン市場における企業合併・買収 (M&A)、合弁事業
  • 認証とライセンシング

第7章 主要企業のプロファイル

• MSD Animal Health
• Ceva Sante Animale
• Syntex
• Bioveta
• Ningbo Sansheng Biological Technology
• Ningbo Second Hormone Factory
• Chifeng Bo-En Pharmaceutical
• Guangzhou Vbio-Pharma
• JALLY
• Ningbo Creator Animal Pharmaceutical

The future of the global serum gonadotrophin for injection market looks promising, with opportunities in the pig, cattle, sheep, and horse markets. The global serum gonadotrophin for injection market is expected to grow with a CAGR of 5.7% from 2025 to 2031. The major drivers for this market are the increasing prevalence of infertility issues worldwide and the growing demand for assisted reproductive technologies.

• Lucintel forecasts that, within the type category, 1000 IU/unit is expected to witness higher growth over the forecast period.
• Within the application category, pig is expected to witness the highest growth.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our 150+ page report.

Emerging Trends in the Serum Gonadotrophin for Injection Market

The serum gonadotrophin for injection market is witnessing several emerging trends that reflect its forward-looking orientation. These trends indicate that reproductive health and fertility-related services are evolving due to changes in patient needs and technological advancements. Stakeholders must understand these trends to capitalize on growth opportunities.

• Trend Towards Customized Therapies: The move toward personalized medicine is accelerating within the serum gonadotrophin market. This trend enhances treatment success by addressing the holistic needs of patients and improving overall patient care.
• Rising Adoption of Biosimilars: The availability of biosimilar gonadotrophins is altering market dynamics. These alternatives offer cost-effective solutions for patients, driving competition and encouraging manufacturers to innovate and reduce treatment costs.
• Increased Use of Telemedicine for Fertility Treatments: Advances in telemedicine are changing how serum gonadotrophins are administered. Telemedicine extends access to treatment, especially for patients in remote areas, making fertility care more accessible and affordable.
• Focus on Education and Awareness: Demand for serum gonadotrophin injections is increasing as efforts to educate patients about reproductive health and fertility treatments intensify. Greater awareness encourages early treatment, positively impacting market growth.
• Regulatory Support for Innovation: Regulatory agencies are increasingly supporting advancements in serum gonadotrophin formulations and shortening approval timelines. This support fosters competition by expediting the launch of new products, providing more treatment options for patients.

These trends are guiding the serum gonadotrophin for injection market toward more accessible, innovative, and effective fertility treatments.

Recent Developments in the Serum Gonadotrophin for Injection Market

The serum gonadotrophin for injection market is undergoing rapid changes driven by developments aimed at enhancing market penetration for fertility treatments. These changes stem from evolving trends in treatments, regulations, and product development that address growing societal needs for effective fertility solutions.

• Introduction of Novel Formulations: Recent innovations include the development of new serum gonadotrophins with improved bioavailability and efficacy. These formulations aim to enhance the success rates for patients undergoing assisted reproductive technology by improving therapeutic effectiveness.
• Expansion of Clinical Applications: Serum gonadotrophins are being applied to a broader range of fertility treatments. This diversification creates new opportunities for manufacturers and increases overall demand for these therapies.
• Research and Development Partnerships: Pharmaceutical companies and research institutions are increasingly collaborating on new serum gonadotrophin products. These partnerships capitalize on synergies to drive productivity and innovation.
• Adoption of Advanced Delivery Methods: There is a growing demand for modern serum gonadotrophin delivery systems, such as prefilled syringes and pen devices. These innovations enhance patient convenience and compliance, leading to improved treatment outcomes.
• Regulatory Advances for Faster Approvals: Regulatory bodies are expediting approvals for new serum gonadotrophin formulations, facilitating the market entry of new treatments. This trend is expected to boost competition and expand treatment options for healthcare providers and patients.

These recent developments reflect the dynamic nature of the injectable serum gonadotrophin market, which is evolving with the help of new technologies, collaborations, and regulatory advancements.

Strategic Growth Opportunities for Serum Gonadotrophin for Injection Market

Strategic growth potential can be seen in various areas of the serum gonadotrophin for injection market across different applications. Given the high demand for fertility treatments, stakeholders can leverage these growth opportunities to increase market participation and effectively meet patient demands.

• Expansion into Emerging Markets: Emerging markets, particularly in Asia and Africa, offer favorable opportunities for the growth of serum gonadotrophin injections. Many patients struggling with infertility will benefit from increased access to fertility services and education, making these regions valuable for market expansion.
• Development of Combination Therapies: Serum gonadotrophins can be combined with other fertility drugs to enhance treatment outcomes. This allows healthcare providers to offer comprehensive treatments for complex cases, improving the quality of fertility services.
• Investment in Patient-Centric Services: Organizations focusing on patient education and patient-centered solutions will continue to have a competitive advantage. Providing resources to help patients understand and manage their treatment builds confidence, improves adherence, and strengthens market presence.
• Focus on Research and Development: It is essential to keep serum gonadotrophin products, such as LHRH and hCG, up-to-date to remain competitive. In a crowded market, companies can gain an edge by developing additional applications for existing products and enhancing current offerings.
• Utilizing Connective Care Technologies: The integration of technologies, such as mobile applications for treatment management, can increase patient engagement. This trend creates new market opportunities, allowing companies to offer comprehensive solutions that support patients throughout the treatment process.

These strategic growth opportunities emphasize the need for innovation, patient orientation, and responsiveness to market evolution in the serum gonadotrophin for injection sector.

Serum Gonadotrophin for Injection Market Driver and Challenges

The serum gonadotrophin for injection market is significantly influenced by various technological, economic, and regulatory factors. Understanding these trends is crucial for stakeholders looking to succeed amid evolving market conditions.

The factors driving the serum gonadotrophin for injection market include:

• Increasing Infertility Rates: Rising infertility rates have created demand for injectable serum gonadotrophins as more people seek treatment options. This need is encouraging companies to expand their offerings of injectable products.
• Advancements in Reproductive Technologies: Innovations such as IVF and ICSI are driving demand for serum gonadotrophins. These advancements provide broader treatment options for patients, contributing to market growth.
• Increasing Acceptance of Fertility Treatment: With growing social acceptance of fertility treatments, more people are seeking help, resulting in higher prescription rates for serum gonadotrophin injections and expanding market opportunities.
• Government Support for Reproductive Health: Many governments are increasing budget allocations for reproductive health initiatives, including infertility treatment. This support not only raises awareness but also improves access to serum gonadotrophin therapies, fostering market growth.

Challenges in the serum gonadotrophin for injection market are:

• Regulatory Compliance and Cost: Complying with regulatory requirements may increase production costs and delay product launches, posing obstacles to market growth and limiting the introduction of new products.
• Market Saturation and Pricing Pressure: With more players entering the serum gonadotrophin market, competition is intensifying. This saturation can lead to price reductions, impacting profitability and sustainability for manufacturers.
• Concerns About Treatment Efficacy: Some patients may question the effectiveness of serum gonadotrophin injections, potentially causing hesitation in seeking treatment. Addressing these concerns through education and research can help build patient confidence and acceptance.

The drivers and challenges in the serum gonadotrophin for injection market highlight the need for a balanced strategy. Companies that align their operations with these trends while addressing market challenges will be well-positioned for long-term success in a competitive environment.

List of Serum Gonadotrophin Companies for Injection Market

Companies in the market compete based on product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, serum gonadotrophin companies for the injection market cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the serum gonadotrophin companies for injection market profiled in this report include-

• MSD Animal Health
• Ceva Sante Animale
• Syntex
• Bioveta
• Ningbo Sansheng Biological Technology
• Ningbo Second Hormone Factory
• Chifeng Bo-En Pharmaceutical
• Guangzhou Vbio-Pharma
• JALLY
• Ningbo Creator Animal Pharmaceutical

Serum Gonadotrophin for Injection by Segment

The study includes a forecast of the global serum gonadotrophin for injection market by type, application, and region.

Serum Gonadotrophin for Injection Market by Type [Analysis by Value from 2019 to 2031]:

• 1000 IU/Unit
• 5000 IU/Unit
• Others

Serum Gonadotrophin for Injection Market by Application [Analysis by Value from 2019 to 2031]:

• Pig
• Cattle
• Sheep
• Horse
• Others

Serum Gonadotrophin for Injection Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Serum Gonadotrophin for Injection Market

The serum gonadotrophin for injection market has seen significant progress recently across major global regions. This growth is attributed to the increasing availability of fertility treatments, advancements in reproductive health research, and approvals for new formulations. As health care providers seek new methods to manage infertility, the evolving market presents both opportunities and challenges for manufacturers and industry stakeholders.

• United States: In the U.S., the FDA has recently approved several new and revised serum gonadotrophin formulations, which will assist patients seeking fertility treatments. With increased awareness of reproductive health and a growing number of assisted reproductive technology (ART) clinics, the market continues to expand. Additionally, telehealth is facilitating easier access to these therapies for patients.
• China: The serum gonadotrophin market in China is rapidly growing due to rising infertility rates and government support for reproductive health programs. Increased collaboration between local manufacturers and international companies is enabling the development of new gonadotrophin therapies. Furthermore, advancements in the country's healthcare system are improving the availability and affordability of fertility services.
• Germany: In recent years, there has been a gradual increase in the use of serum gonadotrophin injections in German fertility clinics. The government is focusing on product development to enhance performance, with many clinical studies underway. Moreover, public awareness programs about fertility treatments have led to a higher uptake of serum gonadotrophins.
• India: The serum gonadotrophin market in India is growing quickly due to rising infertility rates and an expanding middle class. Manufacturers are launching more affordable brands and formulations to make treatment accessible to a broader patient base. Collaboration between healthcare providers and the pharmaceutical sector is also improving patient access to these medications.
• Japan: The serum gonadotrophin market in Japan is highly regulated, focusing on innovative therapies. With the introduction of biosimilar gonadotrophins, the market is expected to see increased competition and reduced treatment costs. Advances in fertility treatment are also contributing to the adoption of serum gonadotrophin injections.

Features of the Global Serum Gonadotrophin for Injection Market

Market Size Estimates: Serum gonadotrophin for injection market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Serum gonadotrophin for injection market size by type, application, and region in terms of value ($B).

Regional Analysis: Serum gonadotrophin for injection market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the serum gonadotrophin for injection market.

Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the serum gonadotrophin for injection market.

Analysis of the competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the serum gonadotrophin for injection market by type (1000 IU/unit, 5000 IU/unit, and others), application (pig, cattle, sheep, horse, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market, and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years, and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Serum Gonadotrophin for Injection Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Serum Gonadotrophin for Injection Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Serum Gonadotrophin for Injection Market by Type
  • 3.3.1: 1000 IU/Unit
  • 3.3.2: 5000 IU/Unit
  • 3.3.3: Others
• 3.4: Global Serum Gonadotrophin for Injection Market by Application
  • 3.4.1: Pig
  • 3.4.2: Cattle
  • 3.4.3: Sheep
  • 3.4.4: Horse
  • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Serum Gonadotrophin for Injection Market by Region
• 4.2: North American Serum Gonadotrophin for Injection Market
  • 4.2.1: North American Market by Type: 1000 IU/Unit, 5000 IU/Unit, and Others
  • 4.2.2: North American Market by Application: Pig, Cattle, Sheep, Horse, and Others
• 4.3: European Serum Gonadotrophin for Injection Market
  • 4.3.1: European Market by Type: 1000 IU/Unit, 5000 IU/Unit, and Others
  • 4.3.2: European Market by Application: Pig, Cattle, Sheep, Horse, and Others
• 4.4: APAC Serum Gonadotrophin for Injection Market
  • 4.4.1: APAC Market by Type: 1000 IU/Unit, 5000 IU/Unit, and Others
  • 4.4.2: APAC Market by Application: Pig, Cattle, Sheep, Horse, and Others
• 4.5: ROW Serum Gonadotrophin for Injection Market
  • 4.5.1: ROW Market by Type: 1000 IU/Unit, 5000 IU/Unit, and Others
  • 4.5.2: ROW Market by Application: Pig, Cattle, Sheep, Horse, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities of the Global Serum Gonadotrophin for Injection Market by Type
  • 6.1.2: Growth Opportunities of the Global Serum Gonadotrophin for Injection Market by Application
  • 6.1.3: Growth Opportunities of the Global Serum Gonadotrophin for Injection Market by Region
• 6.2: Emerging Trends in the Global Serum Gonadotrophin for Injection Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Serum Gonadotrophin for Injection Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Serum Gonadotrophin for Injection Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: MSD Animal Health
• 7.2: Ceva Sante Animale
• 7.3: Syntex
• 7.4: Bioveta
• 7.5: Ningbo Sansheng Biological Technology
• 7.6: Ningbo Second Hormone Factory
• 7.7: Chifeng Bo-En Pharmaceutical
• 7.8: Guangzhou Vbio-Pharma
• 7.9: JALLY
• 7.10: Ningbo Creator Animal Pharmaceutical